Puma Biotechnology (PBYI) Current Assets (2010 - 2026)

Puma Biotechnology's Current Assets history runs 17 years deep, the most recent figure standing at $142.3 million for Q1 2026.

• Quarterly Current Assets rose 7.36% year-over-year to $142.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $142.3 million (up 7.36% YoY) and the FY2025 annual result came in at $162.7 million, up 10.18% from the prior year.
• Current Assets was $142.3 million for Q1 2026 at Puma Biotechnology, down from $162.7 million in the prior quarter.
• Across five years, Current Assets topped out at $162.7 million in Q4 2025 and bottomed at $111.8 million in Q1 2023.
• A 5-year average of $135.5 million and a median of $136.6 million in 2025 frame the typical range for Current Assets.
• Annual changes were most pronounced in 2022 — Current Assets slumped 31.88% — and 2024, when it advanced 27.98%.
• Puma Biotechnology's Current Assets stood at $134.3 million in 2022, then increased by 16.31% to $156.2 million in 2023, then fell by 5.46% to $147.7 million in 2024, then advanced by 10.18% to $162.7 million in 2025, then slipped by 12.56% to $142.3 million in 2026.
• Business Quant data shows PBYI's Current Assets at $142.3 million in Q1 2026, $162.7 million in Q4 2025, and $143.6 million in Q3 2025.